Why this choice changes verification strategy
Specifying commercial off-the-shelf (COTS) Tyvek pouches versus a custom pouch influences the evidence you must collect for bioburden testing and sterilization validation. At trade sessions like those at Medtec China attendees noted that packaging origin alters risk allocation between supplier and manufacturer. For a specifier, that translates into different documentary expectations, sampling plans, and audit focus.

Material and process differences that affect bioburden
Tyvek substrate is consistent in barrier properties, but COTS items typically come with fixed process controls and certificates of conformance, while custom pouches require supplier development records and incoming inspection plans. That difference matters for bioburden because upstream handling and sterilization preconditioning change microbial load trends. Use the terms Tyvek and bioburden sparingly but precisely when documenting deviations.
Relevant standards and retention expectations
Two standards matter most: ISO 11737-1 for bioburden enumeration and USP for sterility testing. List the key expectations explicitly: ISO 11737-1 (microbial recovery and enumeration procedures) and USP <71> (sterility tests — 14-day incubation period). For packaging, ISO 11607 covers design and process validation. When you specify tests, state the retention sample incubation period (e.g., USP <71> requires a 14-day sterility incubation) so labs and suppliers align on sampling windows.

Practical verification workflow for specifiers
Adopt a simple, repeatable workflow: define acceptance criteria, map supplier controls, specify sampling method, run a comparative bioburden study, and review sterilization validation reports. Include these elements in procurement documents: batch-level COA, handling history, and rate-based sampling. During the comparative study, test matched lots of COTS and custom pouches under the same environmental and handling conditions to isolate packaging effects.
What to measure — and why it matters
Focus on three measurable outcomes: average bioburden (CFU/sample), variance between lots, and impact on sterilization cycles expressed as Sterility Assurance Level (SAL) shifts. Measure both mean and spread; a low mean with wide variance is a risk. If a COTS supplier supplies a certificate with unchanged lot-to-lot variance, you can lean on supplier testing. Custom pouches demand more initial verification and ongoing sampling.
Common mistakes and trade-offs
Specifiers often understate handling risk or over-rely on supplier COAs. Another error is failing to lock down environmental monitoring and transfer steps in the user facility — those create hidden bioburden sources. Choose COTS for speed and predictable cost; choose custom for design fit and unique barrier needs. —Remember: predictability reduces verification workload, but custom solutions can reduce device risk when thoughtfully validated.
Field evidence and industry context
Sessions at the Medtec China exhibition and regulatory guidance discussions in Shanghai highlight a consistent message: regulators expect traceable evidence that packaging choice doesn’t increase contamination risk. That real-world anchor—observed audit questions and published standards—shifts the verifier’s emphasis toward documented handling and retention sampling protocols rather than marketing claims.
Three critical evaluation metrics for final selection
1) Bioburden stability: measure lot-to-lot variance over at least three production runs and compare standard deviations. 2) Traceability and documentation: require supplier process maps, COAs, and change-control evidence. 3) Sterilization impact: model SAL changes and verify through a controlled sterilization validation that uses matched pack configurations.
Choose based on measurable outcomes, not assumption — and let supplier transparency lead your sampling intensity. Medtec.
